Biofrontera AG v. Sun Pharmaceutical Industries Inc.

Biofrontera AG, a German biopharmaceutical company specializing in dermatological treatments including photodynamic therapy (PDT) for skin cancers and precancerous lesions, initiated an Inter Partes Review (IPR) against Sun Pharmaceutical Industries Inc.. Sun Pharmaceutical, a global specialty generic pharmaceutical company based in India with a strong U.S. presence in dermatology, owns U.S. Patent No. 11,697,028. This IPR (IPR2024-00874) was filed in response to patent infringement proceedings where Sun Pharmaceutical (through its subsidiary DUSA Pharmaceuticals) accused Biofrontera's Ameluz® drug-device combination, used with the BF-RhodoLED lamp series for PDT, of infringing its patents related to adjustable illuminators for photodynamic therapy. The '028 patent generally covers aspects of adjustable illuminators and light-delivery technology for dermatological PDT.

This specific IPR (IPR2024-00874) was filed at the Patent Trial and Appeal Board (PTAB) on April 30, 2024, but institution of the review was denied on the merits on November 12, 2024, terminating the proceeding. However, the case is notable for its intricate IPR linkage and broader litigation context. While IPR2024-00874 did not proceed, Biofrontera had initiated multiple challenges to Sun Pharmaceutical's patents. A separate IPR (IPR2024-01312), also challenging the validity of U.S. Patent No. 11,697,028, resulted in a Final Written Decision on February 23, 2026, finding all challenged claims of the '028 patent unpatentable. Furthermore, this IPR and its companion cases stem from a broader patent infringement dispute initiated by Sun Pharmaceutical in June 2024 in the U.S. District Court for the District of Massachusetts and at the International Trade Commission (ITC), where Sun Pharma alleged infringement of both the '028 patent and related U.S. Patent No. 11,446,512. The ITC investigation (337-TA-1411) concluded on May 6, 2026, with a finding of Section 337 violation and a judgment on the merits for Sun Pharmaceutical against Biofrontera. The multi-forum litigation highlights the intense competition in the dermatological PDT market, involving key products like Biofrontera's Ameluz® and Sun Pharma/DUSA's LEVULAN® KERASTICK®.

The case information provided in the prompt appears to contain a critical inaccuracy regarding the outcome of IPR2024-00874. The prompt states it was "Terminated: 2024-11-12" and "Status: Institution Denied." However, web search results indicate a different and more significant outcome for IPR2024-00874 and also reveal a related district court case and an ITC investigation.

Specifically, the search results indicate that:

• IPR2024-00874 was instituted and subsequently resulted in a Final Written Decision on February 23, 2026, finding all challenged claims of U.S. Patent No. 11,697,028 unpatentable. The "Institution Denied" status and "Terminated: 2024-11-12" date in the prompt appears to apply to another IPR petition related to a different patent (U.S. Patent No. 11,446,512) or was an interim status, as multiple sources explicitly state a Final Written Decision was issued for IPR2024-00874 regarding patent 11,697,028. One source, however, does indicate "Institution Denied" for IPR2024-00874 with a termination date of 2024-11-12, but this contradicts the other sources regarding the final written decision. This discrepancy needs to be addressed. It's possible the prompt confused IPR2024-00874 with a different IPR, or the initial denial was later overturned or there are multiple petitions. However, the consistent reporting of a Final Written Decision on February 23, 2026, finding claims unpatentable for the '028 patent in IPR2024-00874 is strong evidence. Let's assume the FWD is the ultimate outcome for this specific IPR and address the prompt's stated outcome as an initial, potentially superseded, event or a misunderstanding.

Further, Sun Pharmaceutical Industries Inc. (the patent owner) initiated patent infringement proceedings against Biofrontera AG (the IPR petitioner) in June 2024 in the U.S. District Court for the District of Massachusetts and also filed a complaint with the International Trade Commission (ITC). These parallel proceedings are crucial.

I will now structure the answer based on the actual developments found through the web search, acknowledging and clarifying the discrepancy regarding the IPR's outcome.

Key Legal Developments and Outcome

The legal dispute between Biofrontera AG and Sun Pharmaceutical Industries Inc. involves a patent infringement lawsuit filed by Sun Pharma against Biofrontera in district court and the International Trade Commission (ITC), which prompted Biofrontera to challenge the validity of Sun Pharma's patents through Inter Partes Review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB).

Parallel Proceedings Initiated by Sun Pharmaceutical Industries Inc.

• June 2024: Patent Infringement Litigation Filed

  • Sun Pharmaceutical Industries Inc. initiated patent infringement proceedings against Biofrontera Inc. and its affiliates in the U.S. District Court for the District of Massachusetts. The lawsuit alleged infringement of U.S. Patent No. 11,697,028 and a related patent, U.S. Patent No. 11,446,512. The district court case is docketed as Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc..
  • Concurrently, Sun Pharmaceutical Industries Inc. also filed a complaint with the International Trade Commission (ITC), initiating Investigation No. 337-TA-1411, also in June 2024, asserting infringement of U.S. Patent No. 11,697,028 and U.S. Patent No. 11,446,512 against Biofrontera AG.

• May 6, 2026: ITC Finding of Violation

  • The ITC investigation (337-TA-1411) concluded on May 6, 2026, with a "Judgment on the merits for Plaintiff" and a "Violation Found" against Biofrontera AG, concerning both US11446512B2 and US11697028B2. This finding indicates that the ITC determined imported articles infringed valid claims of the asserted patents.

Biofrontera AG's IPR Challenge

• April 30, 2024: IPR Petition Filed (IPR2024-00874)

  • Biofrontera AG filed a petition for Inter Partes Review (IPR2024-00874) challenging the validity of U.S. Patent No. 11,697,028, owned by Sun Pharmaceutical Industries Inc.. The petition cited Bansal & Larsen prior art against 17 claims, alleging obviousness. This IPR was filed in response to Sun Pharma's infringement proceedings.

• August 22, 2024: Patent Owner Preliminary Response

  • Sun Pharmaceutical Industries Inc. filed its Patent Owner Preliminary Response in IPR2024-00874.

• November 12, 2024: Institution Decision (Initial Denial for IPR2024-00874)

  • The PTAB issued a "Decision Denying Institution of Inter Partes Review" for IPR2024-00874 on November 12, 2024. The provided case metadata in the prompt accurately reflects this initial outcome for IPR2024-00874. However, this seems to have been superseded or was related to a specific set of arguments or claims, as subsequent events indicate the IPR was ultimately instituted.

• August 21, 2024: Another IPR Petition Filed (IPR2024-01312)

  • Separately, Biofrontera Inc. and its affiliates filed another IPR petition, IPR2024-01312, also challenging U.S. Patent No. 11,697,028. This IPR was instituted on February 24, 2025.

• February 23, 2026: Final Written Decision (IPR2024-01312 and IPR2024-00874)

  • The U.S. Patent Trial and Appeal Board issued a Final Written Decision on February 23, 2026, finding all challenged claims of U.S. Patent No. 11,697,028 to be unpatentable. While some sources explicitly link this FWD to IPR2024-00874, others more broadly refer to "the Board" or "Biofrontera's filings," and one PTAB case list shows IPR2024-01312 having a Final Written Decision on February 23, 2026, finding 11697028 in "Final Written Decision" status. Given the conflicting information, it is most accurate to state that a Final Written Decision was issued regarding patent 11,697,028, finding all challenged claims unpatentable, with the date being February 23, 2026. This FWD directly contradicts the prompt's "Institution Denied" status as the final outcome for the '028 patent.
  • Sun Pharma has the right to request a review of this decision or appeal it to the United States Court of Appeals for the Federal Circuit.

Outcome

The IPR proceedings resulted in a significant victory for Biofrontera, as the PTAB issued a Final Written Decision on February 23, 2026, finding all challenged claims of Sun Pharmaceutical's U.S. Patent No. 11,697,028 unpatentable. This outcome directly challenges the basis of Sun Pharma's ongoing infringement claims in the district court and ITC, although the ITC had previously found a violation on May 6, 2026. The effect of the PTAB's unpatentability decision on the ITC's prior finding and the district court litigation would depend on any appeals and the application of collateral estoppel or other legal doctrines. Notably, another IPR petition from Biofrontera relating to the related U.S. Patent No. 11,446,512 was denied review by the Patent Office on administrative, rather than substantive, grounds. Sun Pharma retains the right to appeal the PTAB's Final Written Decision on the '028 patent to the Federal Circuit.

It is important to note the discrepancy between the prompt's provided "Institution Denied" status and the widely reported "Final Written Decision" finding claims unpatentable for IPR2024-00874 and patent 11697028. The search results strongly indicate that while an initial denial might have occurred for IPR2024-00874 on 2024-11-12, a subsequent or different IPR (e.g., IPR2024-01312 also challenging the same patent) resulted in a Final Written Decision of unpatentability on February 23, 2026, which is the most current and significant development concerning the '028 patent's validity. Given the request to cover the "final disposition," the unpatentability finding is the key outcome.The legal proceedings between Biofrontera AG and Sun Pharmaceutical Industries Inc. involve a complex interplay of district court litigation, an International Trade Commission (ITC) investigation, and Inter Partes Review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB). While the prompt initially indicated that IPR2024-00874 concluded with institution denied, web search results reveal a more nuanced and significant outcome for the validity of U.S. Patent No. 11,697,028.

Key Legal Developments and Outcome

Parallel Infringement Proceedings Initiated by Sun Pharmaceutical Industries Inc.

• June 2024: Patent Infringement Litigation and ITC Complaint Filed
  • Sun Pharmaceutical Industries Inc. initiated a patent infringement lawsuit against Biofrontera Inc. and its affiliates in the U.S. District Court for the District of Massachusetts, alleging infringement of U.S. Patent No. 11,697,028 and U.S. Patent No. 11,446,512. The district court case is Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc..
  • Concurrently, Sun Pharmaceutical Industries Inc. filed a complaint with the International Trade Commission (ITC) in June 2024, leading to Investigation No. 337-TA-1411. This complaint also asserted infringement of U.S. Patent No. 11,697,028 and U.S. Patent No. 11,446,512 against Biofrontera AG.
• May 6, 2026: ITC Finding of Violation
  • The ITC investigation (337-TA-1411) concluded on May 6, 2026, with a "Judgment on the merits for Plaintiff" and a "Violation Found" against Biofrontera AG. This determination confirmed that imported articles infringed valid claims of both U.S. Patent No. 11,446,512 and U.S. Patent No. 11,697,028.

Biofrontera AG's IPR Challenges

• April 30, 2024: IPR Petition Filed (IPR2024-00874)
  • Biofrontera AG filed a petition for Inter Partes Review (IPR2024-00874) challenging the validity of U.S. Patent No. 11,697,028, owned by Sun Pharmaceutical Industries Inc.. The petition specifically challenged 17 claims of the patent, citing obviousness based on prior art. This IPR was a direct response to Sun Pharma's infringement allegations.
• August 22, 2024: Patent Owner Preliminary Response
  • Sun Pharmaceutical Industries Inc. submitted its Patent Owner Preliminary Response in IPR2024-00874.
• November 12, 2024: Initial IPR Institution Denial (IPR2024-00874)
  • The PTAB issued a "Decision Denying Institution of Inter Partes Review" for IPR2024-00874 on November 12, 2024. This initial denial aligns with the termination information provided in the case metadata.
• August 21, 2024: Second IPR Petition Filed (IPR2024-01312)
  • Biofrontera Inc. and its affiliates filed another IPR petition, IPR2024-01312, also challenging U.S. Patent No. 11,697,028. This IPR was instituted on February 24, 2025.
• February 23, 2026: Final Written Decision (IPR2024-01312 and IPR2024-00874)
  • On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries Inc.'s U.S. Patent No. 11,697,028 to be unpatentable. While IPR2024-00874 initially faced a denial of institution, a later-filed IPR (IPR2024-01312) challenging the same patent led to this final unpatentability finding. One PTAB case list indicates IPR2024-01312 reached a Final Written Decision on February 23, 2026, concerning patent 11,697,028. This final decision supersedes the earlier institution denial for IPR2024-00874 as the ultimate determination of the patent's validity by the PTAB.

Final Disposition and Current Posture

The PTAB's Final Written Decision on February 23, 2026, finding all challenged claims of U.S. Patent No. 11,697,028 unpatentable, represents a significant outcome in favor of Biofrontera AG. This decision directly impacts the patent infringement litigation in the U.S. District Court for the District of Massachusetts, where Sun Pharma had asserted this patent. Sun Pharmaceutical Industries Inc. retains the right to request a rehearing or appeal the PTAB's decision to the U.S. Court of Appeals for the Federal Circuit. The ITC's earlier finding of a violation on May 6, 2026, could also be subject to appeal or reconsideration in light of the PTAB's unpatentability decision, depending on the stage of the ITC proceedings and the application of legal principles such as collateral estoppel.

Additionally, a separate IPR petition filed by Biofrontera concerning U.S. Patent No. 11,446,512 was denied review by the PTAB on administrative grounds, not on the merits of unpatentability.

The plaintiff in this Inter Partes Review (IPR) proceeding, Biofrontera AG, was represented by counsel from McGuireWoods LLP. While the initial request referred to a "patent infringement case," the provided case number IPR2024-00874 indicates a proceeding before the Patent Trial and Appeal Board (PTAB), which is an administrative validity challenge rather than a district court infringement action. The institution of this IPR was denied on November 12, 2024.

The following attorneys are identified as counsel of record for Biofrontera AG in IPR2024-00874:

• Tyler T. Vanhoutan

  • Role: Counsel
  • Firm: McGuireWoods LLP
  • Office Location: Specific office location for Mr. Vanhoutan within McGuireWoods LLP was not explicitly stated in the provided search results.
  • Relevant Patent Litigation Experience: No specific one-line note on relevant patent litigation experience or notable past cases for Mr. Vanhoutan was readily available in the provided search results.

• George B. Davis

  • Role: Counsel
  • Firm: McGuireWoods LLP
  • Office Location: Specific office location for Mr. Davis within McGuireWoods LLP was not explicitly stated in the provided search results.
  • Relevant Patent Litigation Experience: No specific one-line note on relevant patent litigation experience or notable past cases for Mr. Davis was readily available in the provided search results.

While other attorneys such as Elizabeth D. Ferrill (Finnegan) and Jonathan S. Franklin were mentioned in the search results with relevant patent and IPR experience, the docket information specifically for IPR2024-00874 lists Tyler T. Vanhoutan and George B. Davis from McGuireWoods LLP as counsel for the petitioner, Biofrontera AG. There is no indication from the provided search results that Elizabeth D. Ferrill or Jonathan S. Franklin represented Biofrontera AG in this specific IPR.

I'll research counsel for the defendant/patent owner (Sun Pharmaceutical Industries Inc.) in this matter and the related parallel proceedings.

Key finding: patent owner Sun Pharma's IPR counsel is Desmarais LLP. Let me pin down the individual attorneys of record.

Let me pin down the specific attorneys of record for the patent owner in the IPR and check for later counsel appearances in the parallel litigation.

Bottom line first — and a framing caveat

Note on who the "defendant" is here. This docket (IPR2024-00874) is an inter partes review, not a district court infringement action. Per the case metadata you gave me, Biofrontera AG = plaintiff/petitioner and Sun Pharmaceutical Industries Inc. = defendant/patent owner. So the "defendant side" in IPR2024-00874 is Sun Pharmaceutical Industries, Inc., and its counsel of record in the IPR is Desmarais LLP — the same firm that represents Sun in the parallel D. Mass. infringement suit and the ITC investigation. Because the task also says "patent infringement case," I've added a clearly-separated second block covering the actual defendants in the parallel infringement suit (the four Biofrontera entities).

⚠️ Confidence note: I could confirm the firm of record for the patent owner in IPR2024-00874 (Desmarais LLP) from the PTAB case database, and I could confirm the individual Desmarais attorneys from the parallel docket, ITC filings, and firm press materials. I could not directly read the text of Paper 3 ("Patent Owner's Mandatory Notice," May 21, 2024) or Paper 4 ("Patent Owner's Power of Attorney") in IPR2024-00874, which are the documents that formally list the individual IPR counsel of record. Names below are therefore sourced from related filings, not from Papers 3–4. Attorney-slash-firm pairings I could not source are flagged rather than guessed.

---

A. Defendant/patent owner side — Sun Pharmaceutical Industries, Inc. (counsel of record in IPR2024-00874)

The PTAB docket for IPR2024-00874 identifies the patent owner's counsel as Desmarais LLP (Unified Patents PTAB portal entry: "P.O. COUNSEL — Desmarais LLP"; https://portal.unifiedpatents.com/ptab/case/IPR2024-00874). Docket entries confirming the appearance: Paper 3, Patent Owner's Mandatory Notice (May 21, 2024); Paper 4, Patent Owner's Power of Attorney (May 21, 2024); Paper 6, Patent Owner's Updated Mandatory Notices (Aug. 6, 2024); Paper 7, Patent Owner Preliminary Response (Aug. 22, 2024).

In-house counsel: no Sun/DUSA in-house attorney was identified in any filing, docket entry, or press item I found. Sun Pharma's outside counsel appear to be running the defense/assertion on all three tracks.

Source citations: Desmarais LLP press release, "Desmarais LLP Secures ITC Win for Sun Pharmaceutical in Biofrontera Investigation" (https://www.desmaraisllp.com/desmarais-llp-secures-itc-win-for-sun-pharmaceutical-in-biofrontera-investigation); CourtListener parties page for Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc., 1:24-cv-11637 (https://www.courtlistener.com/docket/68885095/parties/sun-pharmaceutical-industries-inc-v-biofrontera-inc/); Justia docket for 1:24-cv-11637 (Dkts. 1, 2, 5–7, 9, 10, 11); Desmarais filing excerpt signed by G. Higgins in IPR2025-00287.

---

B. Defendants in the parallel infringement suit — Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc., et al., No. 1:24-cv-11637 (D. Mass.) (Judge Indira Talwani)

If your question instead targets the defendants in the actual patent infringement case (the four Biofrontera entities), here is the docket-confirmed list:

Caveats: (1) The D. Mass. case has been stayed since Aug. 23, 2024 pending ITC Inv. No. 337-TA-1411 (Dkt. 21; stay continued at Dkt. 24, Nov. 27, 2024), so the appearance list is short and may not reflect the full trial team. (2) CourtListener/Justia data for this docket is only current through roughly late 2024/early 2025; newer appearances may exist on PACER that I could not retrieve. (3) I could not verify the firms for Larivee, Austin, or Hestin; I saw a "FOLEY‑1411ITC‑" Bates prefix in an ITC filing, which hints Foley Hoag LLP may be one of the respondents' firms, but that is an inference, not a sourced fact.

---

C. Contradiction to flag against the previously generated sections

The prior summary states that the PTAB's Feb. 23, 2026 Final Written Decision in IPR2024-01312 found all challenged claims of the '028 patent unpatentable and treats that as the operative outcome. More recent reporting indicates that FWD was vacated: USPTO Director John A. Squires issued a Director Review decision on July 29, 2026 (IPR2024-01312, Paper 58) that reversed the PTAB's Final Written Decision, denied the petition, and terminated the proceeding, on the ground that the Board failed to adequately explain its departure from the ITC's contrary non-obviousness finding on the same claims and substantially the same evidence. (Source: Getech Law analysis of IPR2024-01312 / 337-TA-1411.) If accurate, the "all claims unpatentable" characterization in the prior sections is now superseded, and the '028 patent survives the Biofrontera IPR challenges — consistent with the metadata's "Institution Denied" posture for IPR2024-00874 and with the ITC's May 6, 2026 violation finding for Sun. I did not independently verify the Director Review decision text on the USPTO PTAB portal, so treat this as a well-sourced-but